Market Intelligence, Clinical Progress, and High-Purity Reagents for NASH, PBC, and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NR1H4/FXR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NR1H4/FXR Ligand Binding Domain (LBD) Recombinant Protein. High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. Expressed in HEK293 or insect cells for native folding. | View NR1H4 Products |
| Mutant Panel | NR1H4/FXR Mutant Variants, including PFIC5-associated regulatory region deletion (loss of isoform 4 transcription) and other site-directed mutants for SAR and mechanistic studies. | View NR1H4 Products |
| Gene Delivery | NR1H4/FXR Promise-ORF / Lentivirus Premade Particles. Full-length ORF for stable reporter cell line construction, >10^8 TU/ml. | View NR1H4 Products |
| Benchmark Ab | Anti-NR1H4/FXR Recombinant Antibody. Research-grade positive control for WB, IHC, and target detection. | View NR1H4 Products |
| Validator | NR1H4/FXR siRNA Set (3 unique sequences). For specific knockdown and target engagement verification in cell-based assays. | View NR1H4 Products |
| Related Target A | RXRA (Retinoid X Receptor Alpha) — Obligate heterodimer partner for DNA binding and transcription. | View RXRA Products |
| Related Target B | GPBAR1 (TGR5) — Membrane bile acid receptor for selectivity counter-screening to avoid pruritus liability. | View GPBAR1 Products |
| Related Target C | FGF19 — Downstream signaling biomarker for pathway validation and PD marker. | View FGF19 Products |
| Related Target D | NR1H3 (LXRα) — Subfamily off-target panel member; cross-reactivity can cause lipogenic side effects. | View NR1H3 Products |
| Related Target E | NR1I2 (PXR) — Xenobiotic sensor; selectivity screen to rule out drug-drug interaction potential. | View NR1I2 Products |
| Related Target F | NR0B2 (SHP) — Downstream transcriptional target of FXR; key for mechanism studies. | View NR0B2 Products |
| Related Target G | FGFR4 — Receptor for FGF19, the hormone induced by FXR activation. | View FGFR4 Products |
The following table addresses critical assay challenges encountered in FXR drug development and highlights the TarMart advantage.
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| LBD Protein Solubility & Stability | Recombinant LBD fragments optimized for high purity (>95%) and strict molecular weight verification, ideal for SPR/TR-FRET. |
| Heterodimer Assay Complexity | Sequence-verified RXRA and FXR proteins available for in vitro co-activator recruitment and dimerization screens. |
| Lack of Robust Cellular Controls | Premade Lentivirus ensures stable, high-copy integration for consistent reporter gene assay development. |
| Target Specificity Validation | Validated siRNA included for background noise reduction and precise specificity checks in hepatic cell lines. |
| Subfamily Counter Screening (LXR/PXR) | Homolog panel proteins (NR1H3 LXRα, NR1I2 PXR) strictly verified by mass spec for selectivity profiling. |
| Co-activator Recruitment Assay | Sequence-verified NR1H4 LBD with intact AF-2 coactivator-binding surface, suitable for TR-FRET and AlphaScreen. |
| Structure-Activity Relationship (SAR) | Defined NR1H4 mutants (including the PFIC5 regulatory deletion) for mechanistic validation and mutant binding studies. |
| Specificity Controls | Clinical benchmark ligands and validated siRNA provided for assay normalization and target dependency confirmation. |
Live NR1H4/FXR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active NR1H4 Clinical Trials
- FXR Agonist Pipeline
- Latest Resistance & Mechanism Research
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for NR1H4/FXR therapeutics has been a focal point in metabolic diseases, particularly for Primary Biliary Cholangitis (PBC) and Metabolic dysfunction-associated steatohepatitis (MASH/NASH). First-generation steroidal agonists, led by Intercept's Obeticholic acid (OCA), secured approval for PBC but faced regulatory scrutiny over tolerability (pruritus) and lipid profile alterations (LDL elevation) in NASH. Consequently, the next wave of R&D is heavily targeting non-steroidal, highly selective partial agonists (e.g., Tropifexor from Novartis, Cilofexor from Gilead, EDP-305 from Enanta) and liver- or intestine-restricted formulations designed to dissociate metabolic efficacy from systemic side effects. The future paradigm shifts toward combination therapies—pairing FXR agonists with GLP-1 receptor agonists (semaglutide), THR-beta agonists (resmetirom), or ACC inhibitors—to achieve synergistic anti-fibrotic and metabolic benefits while maintaining a rigorous safety profile. Additionally, biased signaling (functional selectivity) and tissue-specific targeting are emerging as key differentiators for next-generation FXR modulators.
Competitive Modality & Indication Snapshot
The following table connects market trends to assay needs and illustrates why TarMart reagents are essential.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Steroidal) | Intercept, GSK | PBC, PSC | Biochemical Screening: need high-purity LBD protein for binding assays; selectivity panel (LXR/PXR) to minimize off-target effects. |
| Small Molecule (Non-Steroidal) | Novartis, Gilead, Enanta, Terns | MASH, Liver Fibrosis, Metabolic Syndrome | Co-activator Recruitment Assay: need conformationally active FXR LBD for TR-FRET/AlphaScreen. |
| Tissue-Restricted Agonist | Phenex/BMS, Various biotechs | NASH (Intestinal), Metabolic Syndrome | Cell-based Functional Assay: need Lentivirus for stable intestinal cell line engineering; gut-restricted exposure models. |
| Combination Therapy (FXR + GLP-1 etc.) | Eli Lilly, Novo Nordisk (emerging), Gilead | Advanced MASH, Obesity | Pathway Analysis Tools: need NR0B2/SHP and FGFR4 reagents for downstream signaling studies; dual-target cellular assays. |